Orbimed Advisors Llc bought $12.0M of MBX Biosciences (MBX)
Executed Sep 16 2024, disclosed Sep 17 2024, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Sep 17 2024), the stock returned +9.6% (delay-adjusted); from the execution session (Sep 16 2024), -1.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Orbimed Advisors Llc (Director) filed 15 Form 4 reports as a reporting entity in the trailing twelve months (7 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Sionna Therapeutics, Inc. (SION). Across 7 priced purchase filings, the average 21-session return was +16.9% from execution and +18.9% from disclosure (delay-adjusted; derived). The largest single filing was $38.9M of ELVN (858,646 sh across 3 lots, as filed), executed Jun 22.